Baird Reiterates Buy Rating on Faeth Therapeutics
Baird maintains its buy rating on Faeth Therapeutics, setting a $57 price target, a 145.48% upside from the current price.
Key Points
- Baird reiterated its buy rating on Faeth Therapeutics with a $57 price target on June 26, 2026.
- Baird's $57 price target implies 145.48% upside from Faeth Therapeutics, Inc.'s ($FTH) current $23.22 share price.
- Shares of Faeth Therapeutics traded at $24.67 on Friday, with a 52-week high of $36.76.
- Faeth Therapeutics is a biotechnology company focused on cancer therapeutics, with a market cap of about $636 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Faeth Therapeutics, Inc. (NasdaqCM: FTH) received a reaffirmation of confidence from Baird, which reiterated its buy rating on the company. Analyst Jack Allen set a price target of $57 for the stock on June 26, 2026. Shares of Faeth Therapeutics traded at $24.67 on Friday.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Faeth Therapeutics, Inc. Stock Down 31.4%
Shares of Faeth Therapeutics, Inc. traded near $24.67 on Friday. The company, which operates in the biotechnology industry, has a market capitalization of approximately $636 million. Its stock has experienced a 52-week range from a low of $6.33 to a high of $36.76. The stock's 50-day moving average is $21.65, while the 200-day moving average is $16.72. Faeth Therapeutics has a current ratio of 14.39 and a quick ratio of 14.29, indicating strong liquidity.
$FTH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 26, 2026, Baird reiterated its buy rating on Faeth Therapeutics with a $57 price target. This follows an initiation by HC Wainwright & Co. on June 22, 2026, which also gave a buy rating and set a higher target of $60. The consensus among analysts is a strong buy, with a mean target price of $54 based on five analyst opinions.
About Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. It focuses on discovering and developing therapeutics for cancer patients. The company's pipeline includes PIKTOR, a multi-node inhibitor targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancer, and Solnerstotug, an antibody targeting the immune checkpoint VISTA for solid tumors. Faeth Therapeutics also develops other antibodies for various cancer treatments. The company, originally known as Sensei Biotherapeutics, recently rebranded in June 2026.
Get Faeth Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FTH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.